BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36577036)

  • 1. Physachenolide C is a Potent, Selective BET Inhibitor.
    Zerio CJ; Sivinski J; Wijeratne EMK; Xu YM; Ngo DT; Ambrose AJ; Villa-Celis L; Ghadirian N; Clarkson MW; Zhang DD; Horton NC; Gunatilaka AAL; Fromme R; Chapman E
    J Med Chem; 2023 Jan; 66(1):913-933. PubMed ID: 36577036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and characterization of bromodomain 2-specific inhibitors of BRDT.
    Yu Z; Ku AF; Anglin JL; Sharma R; Ucisik MN; Faver JC; Li F; Nyshadham P; Simmons N; Sharma KL; Nagarajan S; Riehle K; Kaur G; Sankaran B; Storl-Desmond M; Palmer SS; Young DW; Kim C; Matzuk MM
    Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33637650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
    Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
    Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections.
    Modukuri RK; Yu Z; Tan Z; Ta HM; Ucisik MN; Jin Z; Anglin JL; Sharma KL; Nyshadham P; Li F; Riehle K; Faver JC; Duong K; Nagarajan S; Simmons N; Palmer SS; Teng M; Young DW; Yi JS; Kim C; Matzuk MM
    Proc Natl Acad Sci U S A; 2022 May; 119(22):e2122506119. PubMed ID: 35622893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-Guided Design and Synthesis of Pyridinone-Based Selective Bromodomain and Extra-Terminal Domain (BET)-First Bromodomain (BD1) Inhibitors.
    Li Y; Shen Z; Ratia K; Zhao J; Huang F; Dubrovyskyii O; Indukuri D; Fu J; Lozano Ramos O; Thatcher GRJ; Xiong R
    J Med Chem; 2024 Feb; 67(4):2712-2731. PubMed ID: 38295759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic analysis of the BET family in adrenocortical carcinoma: The expression, prognosis, gene regulation network, and regulation targets.
    Situ Y; Liang Q; Zeng Z; Chen J; Shao Z; Xu Q; Lu X; Cui Y; Zhang J; Lu L; Deng L
    Front Endocrinol (Lausanne); 2023; 14():1089531. PubMed ID: 36793283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites.
    Olp MD; Sprague DJ; Goetz CJ; Kathman SG; Wynia-Smith SL; Shishodia S; Summers SB; Xu Z; Statsyuk AV; Smith BC
    ACS Chem Biol; 2020 Apr; 15(4):1036-1049. PubMed ID: 32149490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of
    Sheppard GS; Wang L; Fidanze SD; Hasvold LA; Liu D; Pratt JK; Park CH; Longenecker K; Qiu W; Torrent M; Kovar PJ; Bui M; Faivre E; Huang X; Lin X; Wilcox D; Zhang L; Shen Y; Albert DH; Magoc TJ; Rajaraman G; Kati WM; McDaniel KF
    J Med Chem; 2020 May; 63(10):5585-5623. PubMed ID: 32324999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Benzo[d]imidazole-6-sulfonamides as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain.
    Cipriano A; Milite C; Feoli A; Viviano M; Pepe G; Campiglia P; Sarno G; Picaud S; Imaide S; Makukhin N; Filippakopoulos P; Ciulli A; Castellano S; Sbardella G
    ChemMedChem; 2022 Oct; 17(20):e202200343. PubMed ID: 36040095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The binding mechanism of NHWD-870 to bromodomain-containing protein 4 based on molecular dynamics simulations and free energy calculation.
    Shi M; He J; Weng T; Shi N; Qi W; Guo Y; Chen T; Chen L; Xu D
    Phys Chem Chem Phys; 2022 Feb; 24(8):5125-5137. PubMed ID: 35156677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a Bromodomain and Extra Terminal Domain (BET) Inhibitor with the Selectivity for the Second Bromodomain (BD2) and the Capacity for the Treatment of Inflammatory Diseases.
    Wang Z; Yin L; Xiong Z; Huang F; Yang N; Jiang F; Li H; Cui Y; Ren J; Cheng Z; Jia K; Lu T; Zhu J; Hu Q; Chen Y
    J Med Chem; 2023 Aug; 66(15):10824-10848. PubMed ID: 37478496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies.
    Jiang F; Wei Q; Li H; Li H; Cui Y; Ma Y; Chen H; Cao P; Lu T; Chen Y
    Bioorg Med Chem; 2020 Jan; 28(1):115181. PubMed ID: 31767403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A positron emission tomography imaging probe selectively targeting the BD1 bromodomain and extra-terminal domain.
    Bai P; Yan L; Bagdasarian FA; Wilks MQ; Wey HY; Wang C
    Chem Commun (Camb); 2022 Aug; 58(69):9654-9657. PubMed ID: 35943085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-Molecule Natural Product Physachenolide C Potentiates Immunotherapy Efficacy by Targeting BET Proteins.
    Tewary P; Brooks AD; Xu YM; Wijeratne EMK; Babyak AL; Back TC; Chari R; Evans CN; Henrich CJ; Meyer TJ; Edmondson EF; de Aquino MTP; Kanagasabai T; Shanker A; Gunatilaka AAL; Sayers TJ
    Cancer Res; 2021 Jun; 81(12):3374-3386. PubMed ID: 33837043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
    Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
    J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The bromodomains of BET family proteins can recognize diacetylated histone H2A.Z.
    Patel K; Solomon PD; Walshe JL; Low JKK; Mackay JP
    Protein Sci; 2021 Feb; 30(2):464-476. PubMed ID: 33247496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DW71177: A novel [1,2,4]triazolo[4,3-a]quinoxaline-based potent and BD1-Selective BET inhibitor for the treatment of acute myeloid leukemia.
    Ali I; Cha HJ; Lim B; Chae CH; Youm J; Park WJ; Lee SH; Kim JH; Jeong D; Lim JK; Hwang YH; Roe JS; Woo JS; Lee K; Choi G
    Eur J Med Chem; 2024 Feb; 265():116052. PubMed ID: 38134745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-Guided Design of a Domain-Selective Bromodomain and Extra Terminal N-Terminal Bromodomain Chemical Probe.
    Bradley E; Fusani L; Chung CW; Craggs PD; Demont EH; Humphreys PG; Mitchell DJ; Phillipou A; Rioja I; Shah RR; Wellaway CR; Prinjha RK; Palmer DS; Kerr WJ; Reid M; Wall ID; Cookson R
    J Med Chem; 2023 Dec; 66(23):15728-15749. PubMed ID: 37967462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-Based Discovery and Optimization of Furo[3,2-
    Li J; Zhang C; Xu H; Wang C; Dong R; Shen H; Zhuang X; Chen X; Li Q; Lu J; Zhang M; Wu X; Loomes KM; Zhou Y; Zhang Y; Liu J; Xu Y
    J Med Chem; 2022 Apr; 65(7):5760-5799. PubMed ID: 35333526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4.
    Zengerle M; Chan KH; Ciulli A
    ACS Chem Biol; 2015 Aug; 10(8):1770-7. PubMed ID: 26035625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.